Ninlaro (ixazomib; Takeda) capsules are now available through an open distribution model that includes physician in-office dispensing and a specialty pharmacy network. Specialty pharmacies in the Ninlaro 1Point network include: Accredo, ACS/Omnicare Specialty Care Group, Avella, Axium, Biologics, Inc., CVS/specialty, Diplomat Pharmacy, US Bioservices, and Walgreens.

Ninlaro was approved in November 2015 for use in combination with lenalidomide (RevlimidCelgene) and dexamethasone to treat patients with multiple myeloma who have received ≥1 prior therapy. Ninlaro is an oral proteasome inhibitor that works by blocking enzymes from multiple myeloma cells.

RELATED: Ninlaro Approved for Multiple Myeloma

It was granted priority review and orphan drug designations by the FDA. Ninlaro is available as 2.3mg, 3mg, and 4mg strength capsules in single-capsule blister packs and 3-count cartons. 

For more information call (844) 617-6468 or visit